Results 181 to 190 of about 5,702,046 (400)
Molecular Oncology, EarlyView.In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková +14 more
wiley +1 more source
Health Behavior Theory and cumulative knowledge regarding health behaviors: are we moving in the right direction? [PDF]
, 2005 Seth M. Noar, Rick S. Zimmerman
openalex +1 more source
Safeguarding the Right to Health of the Elderly in Rural China: A Legal Analysis. [PDF]
Risk Manag Healthc Policy, 2023 Chen Q, Tian W, Zheng L, Li T.
europepmc +1 more source
Molecular Oncology, EarlyView.In thyroid cancer patients, high‐dose (≥7.4 GBq) radioactive iodine therapy (RAIT) was associated with a higher prevalence of clonal hematopoiesis (variant allele frequency >2%) in individuals aged ≥50 years (OR = 2.44). In silico analyses showed that truncating PPM1D mutations conferred a selective advantage under these conditions.
Jaeryuk Kim +11 more
wiley +1 more source
Contraception and sexual health: are we on the right track? [PDF]
, 2005 J. H. Tripp
openalex +1 more source
Chimeric diphtheria toxin–CCL8 cytotoxic peptide for breast cancer management
Molecular Oncology, EarlyView.DTCCL8 is a recombinant fusion toxin that targets cancer cells expressing chemokine receptors. By combining diphtheria toxin with CCL8, DTCCL8 binds to multiple receptors on tumor cells and induces selective cytotoxicity. This strategy enables receptor‐mediated targeting of cancer and may support the development of chemokine‐guided therapeutics ...
Bernardo Chavez +5 more
wiley +1 more source
Health should be seen as a human right, global campaign says [PDF]
, 2005 S. Arie
openalex +1 more source
Realising the right to health for all people-UHC is the umbrella to deliver health for all. [PDF]
Lancet Glob Health, 2023 Espinosa MF +9 more
europepmc +1 more source
ITGAV and SMAD4 influence the progression and clinical outcome of pancreatic ductal adenocarcinoma
Molecular Oncology, EarlyView.In SMAD4‐positive pancreatic ductal adenocarcinoma (PDAC), integrin subunit alpha V (ITGAV) activates latent TGF‐β, which binds to the TGF‐β receptor and phosphorylates SMAD2/3. The activated SMAD2/3 forms a complex with SMAD4, and together they translocate to the nucleus, modulating gene expression to promote proliferation, migration, and invasion. In
Daniel K. C. Lee +9 more
wiley +1 more source